Browse by Section 100 Item List

Highly Specialised Drugs Program (Private Hospital)

For Pharmaceutical Benefits Scheme (PBS) Highly Specialised Drugs prescribed through private hospitals, claiming and approval of authority prescriptions is administered by Services Australia. Highly Specialised Drugs prescribed in private hospitals are Authority Required items. Application for authorisation can be made by either:

  • posting an Authority Prescription form and other application form(s), where applicable to Services Australia
  • using the form upload facility in Health Professional Online Services (HPOS)
  • using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS)
  • using the Services Australia free-call service for PBS Complex Drugs Programs enquiries (1800 700 270) or
  • using the appropriate Streamlined code.

Prescribers must quote the provider number of the hospital when applying. Maximum quantities and repeats for Highly Specialised Drugs are listed in the PBS Schedule. Authority approvals are required for prescriptions where the dose is above the determined maximum quantity and/or number of repeats.

Private hospital prescriptions for Highly Specialised Drugs can be dispensed by an approved private hospital dispensary or by a community pharmacy. A patient will be required to pay a contribution for each supply of a highly specialised drug at the same rate as the PBS.

The remuneration rates for Highly Specialised Drugs prescribed through private hospitals comprise the normal PBS ready-prepared dispensing fee plus a mark-up ascertained as follows:

  • 10% for drugs with an ex-manufacturer price of less than $40
  • $4 for drugs with an ex-manufacturer price of between $40 and $100
  • 4% for drugs with an ex-manufacturer price of between $100.01 and $1000
  • $40 for drugs with an ex-manufacturer price of greater than $1000.

Reciprocal Health Care Agreement – Where a patient is entitled to be treated as an eligible person as a visitor from a country with which Australia has entered into a Reciprocal Health Care Agreement, the supply will be limited to the original prescription only. Repeat prescriptions for these patients are not permitted.

  • Legend
  • MPMedical Practitioner
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MP 6492Q DARBEPOETIN ALFAdarbepoetin alfa 100 microgram/0.5 mL injection, 0.5 mL pen device 8 8 5
MP 6326Y DARBEPOETIN ALFAdarbepoetin alfa 100 microgram/0.5 mL injection, 4 x 0.5 mL syringes 2 8 5
MP 6493R DARBEPOETIN ALFAdarbepoetin alfa 150 microgram/0.3 mL injection, 0.3 mL pen device 8 8 5
MP 6365B DARBEPOETIN ALFAdarbepoetin alfa 150 microgram/0.3 mL injection, 4 x 0.3 mL syringes 2 8 5
MP 6488L DARBEPOETIN ALFAdarbepoetin alfa 20 microgram/0.5 mL injection, 0.5 mL pen device 8 8 5
MP 6321Q DARBEPOETIN ALFAdarbepoetin alfa 20 microgram/0.5 mL injection, 4 x 0.5 mL syringes 2 8 5
MP 6322R DARBEPOETIN ALFAdarbepoetin alfa 30 microgram/0.3 mL injection, 4 x 0.3 mL syringes 2 8 5
MP 6489M DARBEPOETIN ALFAdarbepoetin alfa 40 microgram/0.4 mL injection, 0.4 mL pen device 8 8 5
MP 6323T DARBEPOETIN ALFAdarbepoetin alfa 40 microgram/0.4 mL injection, 4 x 0.4 mL syringes 2 8 5
MP 6324W DARBEPOETIN ALFAdarbepoetin alfa 50 microgram/0.5 mL injection, 4 x 0.5 mL syringes 2 8 5
MP 6490N DARBEPOETIN ALFAdarbepoetin alfa 60 microgram/0.3 mL injection, 0.3 mL pen device 8 8 5
MP 6325X DARBEPOETIN ALFAdarbepoetin alfa 60 microgram/0.3 mL injection, 4 x 0.3 mL syringes 2 8 5
MP 6491P DARBEPOETIN ALFAdarbepoetin alfa 80 microgram/0.4 mL injection, 0.4 mL pen device 8 8 5
MP 6438W DARBEPOETIN ALFAdarbepoetin alfa 80 microgram/0.4 mL injection, 4 x 0.4 mL syringes 2 8 5
MP 6320P DARBEPOETIN ALFAdarbepoetin alfa 10 microgram/0.4 mL injection, 4 x 0.4 mL syringes 2 8 5
MP 11236J DEFERASIROXdeferasirox 125 mg dispersible tablet, 28 6 168 2
MP 11241P DEFERASIROXdeferasirox 125 mg dispersible tablet, 28 6 168 2
MP 6499C DEFERASIROXdeferasirox 125 mg dispersible tablet, 28 6 168 5
MP 11238L DEFERASIROXdeferasirox 250 mg dispersible tablet, 28 6 168 2
MP 11244T DEFERASIROXdeferasirox 250 mg dispersible tablet, 28 6 168 2
MP 6500D DEFERASIROXdeferasirox 250 mg dispersible tablet, 28 6 168 5
MP 11232E DEFERASIROXdeferasirox 500 mg dispersible tablet, 28 6 168 2
MP 11243R DEFERASIROXdeferasirox 500 mg dispersible tablet, 28 6 168 2
MP 9600G DEFERASIROXdeferasirox 500 mg dispersible tablet, 28 6 168 5
MP 11510T DEFERASIROXdeferasirox 180 mg tablet, 30 6 180 2
MP 11546Q DEFERASIROXdeferasirox 180 mg tablet, 30 6 180 5
MP 11557G DEFERASIROXdeferasirox 180 mg tablet, 30 6 180 2
MP 11496C DEFERASIROXdeferasirox 360 mg tablet, 30 6 180 5
MP 11511W DEFERASIROXdeferasirox 360 mg tablet, 30 6 180 2
MP 11547R DEFERASIROXdeferasirox 360 mg tablet, 30 6 180 2
MP 11545P DEFERASIROXdeferasirox 90 mg tablet, 30 6 180 5
MP 11548T DEFERASIROXdeferasirox 90 mg tablet, 30 6 180 2
MP 11558H DEFERASIROXdeferasirox 90 mg tablet, 30 6 180 2
MP 9638G DEFERIPRONEdeferiprone 100 mg/mL oral liquid, 250 mL 5 5 5
MP 6416Q DEFERIPRONEdeferiprone 500 mg tablet, 100 3 300 5
MP 11724C DEFERIPRONEdeferiprone 1 g tablet, 50 6 300 5
MP 6270B DESFERRIOXAMINEdesferrioxamine mesilate 2 g injection, 1 vial 60 60 5
MP 6113R DESFERRIOXAMINEdesferrioxamine mesilate 500 mg injection, 10 vials 40 400 5
MP 6120D DORNASE ALFAdornase alfa 2.5 mg/2.5 mL inhalation solution, 30 x 2.5 mL ampoules 2 60 5
MPNP 6249X DOXORUBICIN HYDROCHLORIDE (AS PEGYLATED LIPOSOMAL)doxorubicin hydrochloride (as pegylated liposomal) 20 mg/10 mL injection, 10 mL vial 4 4 5
MP 12294C DUPILUMABdupilumab 300 mg/2 mL injection, 2 x 2 mL syringes 1 2 5
MP 12310X DUPILUMABdupilumab 300 mg/2 mL injection, 2 x 2 mL syringes 1 2 8
MP 12313C DUPILUMABdupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes 1 2 8
MP 12316F DUPILUMABdupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes 1 2 5